The facility will also install modernized equipment to improve efficiency and reliability while reducing its greenhouse gas ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

Lilly's fourth-quarter profit doubles, driven by diabetes and obesity treatments. Strong revenue and forecast for 2025.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Lilly's fourth-quarter earnings, released before the market opened Thursday, surpassed analysts' expectations by millions.

The project will expand Ingredion’s capabilities for delivering texture innovations to growing end markets while bolstering ...

Purdue announced an exciting new collaboration and earned accolades for several online programs this week. Derek Schultz has it all in the latest edition of “Purdue News Now” from Indianapolis. Plus, ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

Solbinsiran sodium is under clinical development by Eli Lilly and Co and currently in Phase ... Africa and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US. For a complete picture ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...